Search for: "Mylan Pharmaceuticals"
Results 41 - 60
of 738
Sort by Relevance
|
Sort by Date
1 Jul 2022, 10:02 am
Mylan Pharmaceuticals Inc., No. 21-1567, also focuses on the written description requirement – asking what level of disclosure is necessary for a claim limitation requiring a therapeutic treatment to be “effective. [read post]
19 Apr 2022, 2:41 am
Ono: Multiple approved products covered by the same patentThe case in Ono Pharmaceutical v Commissioner of Patents ([2021] FCA 643) related to Ono's PD-1 inhibitor OPDIVO (nivolumab). [read post]
14 Apr 2022, 11:42 am
Author Karjis Sambrans Licence CC BY 2.0 Source Wikimedia CommonsJane LambertPatents Court (Mr Ian Karet) Neurim Pharmaceuticals (1991) Ltd another v Generics (UK) Ltd (T/A Viatris) and another [2021] EWHC 2897 (Pat) (29 Ort 2021)This was an application by Generics (UK) Limited and Mylan UK Healthcare Limited ("Mylan") for a stay of the expedited trial that had been ordered by Mr Justice Mellor [read post]
30 Mar 2022, 7:34 am
Author The Judicial Office, UK Licence CC BYSA 4.0 Source Wikimedia CommonsJane LambertPatents Court (Mr Justice Mellor) Neurim Pharmaceuticals (1991) Ltd and another v Generics UK Ltd (t/a Mylan) and another [2021] EWHC 2198 (Pat) (2 Aug 2021)This case shows how quickly the English courts can move to resolve disputes when there is a need for them do so. [read post]
17 Mar 2022, 9:06 pm
Mylan Pharmaceuticals Inc. [read post]
17 Mar 2022, 2:32 pm
Mylan Pharmaceuticals Inc. [read post]
16 Mar 2022, 9:57 am
Mylan Pharmaceuticals (Fed. [read post]
7 Mar 2022, 2:07 pm
In 2017, Mylan paid $465 million for misclassifying EpiPen® as a generic drug to avoid paying the higher rebates owed on brand name drugs. [read post]
2 Mar 2022, 7:50 am
Mylan Pharmaceuticals Inc. [read post]
7 Feb 2022, 3:00 am
Meade J’s judgment (Neurim Pharmaceutical (1991) Limited and Anor v Generics (UK) Limited t/a Viatris and Anor [2022] EWHC 109 (Pat)), which can be found here, was handed down on 24 January 2022. [read post]
3 Feb 2022, 8:57 pm
Food and Drug Administration announced approval to Mylan Pharmaceuticals for a generic form of Allergan's RESTASIS® (Cyclosporine Ophthalmic Emulsion 0.05%) product for treatment of chronic dry eye. [read post]
1 Feb 2022, 1:22 pm
Mylan Pharmaceuticals Inc., Docket No. 21-01729 (Fed. [read post]
20 Jan 2022, 4:41 pm
Mylan Pharmaceuticals is recalling certain Semglee prefilled insulin injection pens because they may not be properly labeled. [read post]
20 Jan 2022, 4:19 am
In denying petitions from consumer tech giant Apple and generic pharmaceutical firm Mylan Laboratories, SCOTUS has ended the latest challenge to the PTAB’s NHK/Fintiv rule, which has raised... [read post]
20 Jan 2022, 4:19 am
In denying petitions from consumer tech giant Apple and generic pharmaceutical firm Mylan Laboratories, SCOTUS has ended the latest challenge to the PTAB’s NHK/Fintiv rule, which has raised the ire of many entities who have found the PTAB to be a very valuable backdoor towards patent invalidation outside of U.S. district court. [read post]
11 Jan 2022, 6:04 am
Mylan Pharmaceuticals Inc. [read post]
4 Jan 2022, 6:00 am
Cir. 2021) 2021-1729 AstraZeneca AB and AstracZeneca Pharmacueticals LP (AstraZeneca) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
30 Dec 2021, 8:07 am
Mylan Pharmaceuticals Inc., November 30, 2021, Reyna, J.). [read post]
13 Dec 2021, 6:50 am
” The piece notes that “Mylan NV’s now-shuttered West Virginia plant was warned by the FDA in 2018 for a host of quality violations, not the first time inspectors had raised concerns there. [read post]
9 Dec 2021, 7:15 am
On December 8, the United States Court of Appeals for the Federal Circuit (CAFC), in a precedential decision authored by Judge Stoll, vacated a judgment of infringement against Mylan Pharmaceuticals Inc. and affirmed the nonobvious determination of the United States District Court for the Northern District of West Virginia. [read post]
